POST-TEST

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which combination regimen recently 4. Which type of agent is zanidatamab received FDA approval on the basis of (ZW25), an investigational drug that has results from the BEACON CRC trial yielded promising responses in patients evaluating encorafenib/ with with heavily pretreated biliary, colorectal or without versus investiga- and gastroesophageal cancer? tor’s choice of irinotecan/cetuximab or a. Anti-PD-1/PD-L1 antibody FOLFIRI/cetuximab for patients with b. Angiogenesis inhibitor metastatic (mCRC) c. Cancer cell stemness inhibitor with BRAF V600E mutations? d. Bispecific antibody against HER2 a. Encorafenib/cetuximab/binimetinib only 5. Which of the following patients with RAS b. Encorafenib/cetuximab only wild-type mCRC derive clinical benefit c. Encorafenib/cetuximab and from the addition of EGFR antibodies to encorafenib/cetuximab/binimetinib first-line ? a. Patients with left-sided primary 2. Which of the following drug descriptions disease best reflects the mechanism of action of b. Patients with right-sided primary deruxtecan? disease a. Immune checkpoint inhibitor b. Antibody-drug conjugate 6. Which of the following CRC charac- c. Anti-VEGF receptor inhibitor teristics is predictive of benefit from treatment with immune checkpoint 3. Which of the following statements is inhibition (eg, )? true about the promising results of the a. High microsatellite instability (MSI) ongoing Phase II DESTINY-CRC01 trial b. High tumor mutation burden investigating for c. Both a and b patients with unresectable or metastatic HER2-expressing CRC? d. Neither a nor b a. Responses were observed among 7. Which of the following is a common side only those patients who had previ- effect of TAS-102? ously received any HER2-directed therapy a. Hand-foot syndrome b. Responses were observed among b. Aphonia only those patients who had no c. Neutropenia prior exposure to HER2-directed therapy 8. Based on results of the KEYNOTE-177 trial, pembrolizumab is FDA approved for c. Responses were observed patients with mCRC in which setting? regardless of prior exposure to HER2-directed therapy a. As first-line therapy for patients with MSI-high disease b. As second-line therapy for patients with MSI-high disease c. As third- or later-line therapy for patients with microsatellite disease

QID 2725 POST-TEST

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. In the discovery cohort of the Circulating 10. The ongoing Phase III CanStem303C Cell-Free Genome Atlas Study, which of trial is evaluating which agent in combi- the following assays was established as nation with FOLFIRI with or without the best liquid-biopsy platform for early for previously treated detection of cancer? mCRC? a. Whole genome sequencing a. TAS-102 b. Targeted mutation assay b. Trastuzumab deruxtecan c. Methylation-based assay c. Encorafenib d. Napabucasin

QID 2725